SCHEMBL2997908

SCHEMBL2997908

CC(C)(C)c1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccc(Cl)c(F)c4)cs3)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
MAPT P10636 2/20 0.57
USP2 O75604 1/20 0.57
RECQL P46063 1/20 0.57
HSD17B10 Q99714 1/20 0.57
MAPK1 P28482 2/20 0.51
HSD11B1 P28845 9/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 3/20 0.48
TDP1 Q9NUW8 1/20 0.46
AR P10275 1/20 0.45
POLB P06746 1/20 0.44
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GBA1 P04062 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002658 0.93 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3010351 0.92 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3013812 0.91 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3010149 0.89 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3018178 0.89 SMN1; SMN2 (0.80) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3016696 0.89 SMN1; SMN2 (0.69) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3010820 0.88 SMN1; SMN2 (0.68) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3010352 0.87 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3018617 0.87 SMN1; SMN2 (0.66) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3008962 0.87 SMN1; SMN2 (0.66) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.